Astrazeneca Plc Earnings

Astrazeneca Plc’s revenue jumped 7.17% since last year same period to $13588Mn in the Q1 2025. On a quarterly growth basis, Astrazeneca Plc has generated -8.75% fall in its revenue since last 3-months.

Astrazeneca Plc’s net profit jumped 33.82% since last year same period to $2916Mn in the Q1 2025. On a quarterly growth basis, Astrazeneca Plc has generated 94.4% jump in its net profits since last 3-months.

Astrazeneca Plc’s net profit margin jumped 24.87% since last year same period to 21.46% in the Q1 2025. On a quarterly growth basis, Astrazeneca Plc has generated 113.04% jump in its net profit margins since last 3-months.

Astrazeneca Plc’s price-to-earnings ratio after this Q1 2025 earnings stands at 28.53.

Astrazeneca Plc’s earning per share (EPS) estimates for the current quarter stand at 1.12 - a 7.66% jump from last quarter’s estimates.

Astrazeneca Plc’s earning per share (EPS) estimates for the current year stand at 1.12.

Astrazeneca Plc’s earning per share (EPS) fell -9.32% since last year same period to 0.93 in the Q1 2025. This indicates that the Astrazeneca Plc has generated -9.32% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Astrazeneca Plc’s return on assets (ROA) stands at 0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Astrazeneca Plc’s return on equity (ROE) stands at 0.2.

Astrazeneca Plc declared 1.05 dividend per share during the earnings announcement for Q1 2025.